<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Jin C</submitter><funding>National Key R&amp;amp;D Program of China</funding><funding>National Key R&amp;D Program of China</funding><funding>CAMS Innovation Fund for Medical Sciences</funding><funding>National Natural Science Foundation of China</funding><pagination>1385-1395</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9106624</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>33(6)</volume><pubmed_abstract>The present study was the first prospective cohort evaluated the efficacy and safety of different doses of calcitriol in XLH children. The results suggested that a dose of 40 ng/kg/day calcitriol, compared with 20 ng/kg/day, was more effective in relieving the rickets, with similar safety outcomes. Further investigations were expected to set more dose groups.&lt;h4>Introduction&lt;/h4>Dose recommended for calcitriol in X-linked hypophosphatemia (XLH) varies in different studies. Therefore, we aimed to compare the efficacy as well as the safety of 20 ng/kg/d and 40 ng/kg/d calcitriol in Chinese XLH pediatrics population.&lt;h4>Methods&lt;/h4>A 2-year, randomized, open-label, prospective study recruited 68 XLH children, which were randomized to receive either 40 ng/kg/day or 20 ng/kg/day calcitriol. Eff</pubmed_abstract><journal>Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA</journal><pubmed_title>The efficacy and safety of different doses of calcitriol combined with neutral phosphate in X-linked hypophosphatemia: a prospective study.</pubmed_title><pmcid>PMC9106624</pmcid><funding_grant_id>2016-I2M-3-003</funding_grant_id><funding_grant_id>2018YFA 0800801</funding_grant_id><funding_grant_id>81970757</funding_grant_id><pubmed_authors>Xu L</pubmed_authors><pubmed_authors>Xing X</pubmed_authors><pubmed_authors>Wu B</pubmed_authors><pubmed_authors>Zhao Z</pubmed_authors><pubmed_authors>Li M</pubmed_authors><pubmed_authors>Meng X</pubmed_authors><pubmed_authors>Xia W</pubmed_authors><pubmed_authors>Jiang Y</pubmed_authors><pubmed_authors>Wang O</pubmed_authors><pubmed_authors>Jin C</pubmed_authors><pubmed_authors>Ni X</pubmed_authors><pubmed_authors>Zhang C</pubmed_authors><pubmed_authors>Chi Y</pubmed_authors><pubmed_authors>Jiajue R</pubmed_authors></additional><is_claimable>false</is_claimable><name>The efficacy and safety of different doses of calcitriol combined with neutral phosphate in X-linked hypophosphatemia: a prospective study.</name><description>The present study was the first prospective cohort evaluated the efficacy and safety of different doses of calcitriol in XLH children. The results suggested that a dose of 40 ng/kg/day calcitriol, compared with 20 ng/kg/day, was more effective in relieving the rickets, with similar safety outcomes. Further investigations were expected to set more dose groups.&lt;h4>Introduction&lt;/h4>Dose recommended for calcitriol in X-linked hypophosphatemia (XLH) varies in different studies. Therefore, we aimed to compare the efficacy as well as the safety of 20 ng/kg/d and 40 ng/kg/d calcitriol in Chinese XLH pediatrics population.&lt;h4>Methods&lt;/h4>A 2-year, randomized, open-label, prospective study recruited 68 XLH children, which were randomized to receive either 40 ng/kg/day or 20 ng/kg/day calcitriol. Eff</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Jun</publication><modification>2025-04-04T03:19:21.429Z</modification><creation>2024-11-05T22:58:20.716Z</creation></dates><accession>S-EPMC9106624</accession><cross_references><pubmed>35088103</pubmed><doi>10.1007/s00198-021-06221-w</doi></cross_references></HashMap>